Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Nov 26

PMID 36429122

Authors

Hussein Kadhem Al-Hakeim

Mazin Fadhil Altufaili

Abbas F Almulla

Shatha Rouf Moustafa

Michael Maes

Affiliations

Soon will be listed here.

Abstract

Background: a significant percentage of methamphetamine (MA) dependent patients develop psychosis. The associations between oxidative pathways and MA-induced psychosis (MIP) are not well delineated.

Objective: the aim of this study is to delineate whether acute MA intoxication in MA dependent patients is accompanied by increased nitro-oxidative stress and whether the latter is associated with MIP.

Method: we recruited 30 healthy younger males and 60 acutely intoxicated males with MA dependence and assessed severity of MA use and dependence and psychotic symptoms during intoxication, and serum oxidative toxicity (OSTOX) biomarkers including oxidized high (oxHDL) and low (oxLDL)-density lipoprotein, myeloperoxidase (MPO), malondialdehyde (MDA), and nitric oxide (NO), and antioxidant defenses (ANTIOX) including HDL-cholesterol, zinc, glutathione peroxidase (GPx), total antioxidant capacity (TAC), and catalase-1.

Results: a large part (50%, n = 30) of patients with MA dependence could be allocated to a cluster characterized by high psychosis ratings including delusions, suspiciousness, conceptual disorganization and difficulties abstract thinking and an increased OSTOX/ANTIOX ratio. Partial Least Squares analysis showed that 29.9% of the variance in MIP severity (a first factor extracted from psychosis, hostility, excitation, mannerism, and formal thought disorder scores) was explained by HDL, TAC and zinc (all inversely) and oxLDL (positively). MA dependence and dosing explained together 44.7% of the variance in the OSTOX/ANTIOX ratio.

Conclusions: MA dependence and intoxication are associated with increased oxidative stress and lowered antioxidant defenses, both of which increase risk of MIP during acute intoxication. MA dependence is accompanied by increased atherogenicity due to lowered HDL and increased oxLDL and oxHDL.

Citing Articles

Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions.

Nohesara S, Mostafavi Abdolmaleky H, Thiagalingam S Brain Sci. 2024; 14(8).

PMID: 39199463 PMC: 11352452. DOI: 10.3390/brainsci14080769.

The General Neurocognitive Decline in Patients with Methamphetamine Use and Transient Methamphetamine-induced Psychosis is Primarily Determined by Oxidative and AGE-RAGE Stress.

Maes M, Altufaili M, Alhaideri A, Moustafa S, Stoyanova K, Niu M Curr Top Med Chem. 2024; 24(20):1816-1828.

PMID: 38984578 DOI: 10.2174/0115680266320808240709061445.

Methamphetamine (MA) use and MA-induced psychosis are associated with increasing aberrations in the compensatory immunoregulatory system, interleukin-1α, and CCL5 levels.

Kalayasiri R, Dadwat K, Thika S, Sirivichayakul S, Maes M Transl Psychiatry. 2023; 13(1):361.

PMID: 37996407 PMC: 10667231. DOI: 10.1038/s41398-023-02645-6.

References

Honda H, Ueda M, Kojima S, Mashiba S, Michihata T, Takahashi K . Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis. 2011; 220(2):493-501. DOI: 10.1016/j.atherosclerosis.2011.10.038. View

Arunogiri S, Foulds J, McKetin R, Lubman D . A systematic review of risk factors for methamphetamine-associated psychosis. Aust N Z J Psychiatry. 2018; 52(6):514-529. DOI: 10.1177/0004867417748750. View

Govitrapong P, Boontem P, Kooncumchoo P, Pinweha S, Namyen J, Sanvarinda Y . Increased blood oxidative stress in amphetamine users. Addict Biol. 2009; 15(1):100-2. DOI: 10.1111/j.1369-1600.2009.00176.x. View

Glasner-Edwards S, Mooney L . Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014; 28(12):1115-26. PMC: 5027896. DOI: 10.1007/s40263-014-0209-8. View

Fitzmaurice P, Tong J, Yazdanpanah M, Liu P, Kalasinsky K, Kish S . Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J Pharmacol Exp Ther. 2006; 319(2):703-9. DOI: 10.1124/jpet.106.109173. View

Mirecki A, Fitzmaurice P, Ang L, Kalasinsky K, Peretti F, Aiken S . Brain antioxidant systems in human methamphetamine users. J Neurochem. 2004; 89(6):1396-408. DOI: 10.1111/j.1471-4159.2004.02434.x. View

Maes M, Sirivichayakul S, Matsumoto A, Maes A, Michelin A, de Oliveira Semeao L . Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity. Mol Neurobiol. 2020; 57(5):2333-2345. DOI: 10.1007/s12035-020-01882-w. View

Zweben J, Cohen J, Christian D, Galloway G, Salinardi M, Parent D . Psychiatric symptoms in methamphetamine users. Am J Addict. 2004; 13(2):181-90. DOI: 10.1080/10550490490436055. View

Moylan S, Berk M, Dean O, Samuni Y, Williams L, ONeil A . Oxidative & nitrosative stress in depression: why so much stress?. Neurosci Biobehav Rev. 2014; 45:46-62. DOI: 10.1016/j.neubiorev.2014.05.007. View

10.

Weich L, Pienaar W . Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. Afr J Psychiatry (Johannesbg). 2009; 12(3):213-7. DOI: 10.4314/ajpsy.v12i3.48496. View

11.

Glasner-Edwards S, Mooney L, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R . Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008; 35(4):445-50. DOI: 10.1016/j.jsat.2007.12.004. View

12.

Boroujeni M, Peirouvi T, Shaerzadeh F, Ahmadiani A, Abdollahifar M, Aliaghaei A . Differential gene expression and stereological analyses of the cerebellum following methamphetamine exposure. Addict Biol. 2019; 25(1):e12707. DOI: 10.1111/adb.12707. View

13.

Almulla A, Vasupanrajit A, Tunvirachaisakul C, Al-Hakeim H, Solmi M, Verkerk R . The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry. 2022; 27(9):3679-3691. DOI: 10.1038/s41380-022-01552-4. View

14.

Lecomte T, Dumais A, Dugre J, Potvin S . The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Res. 2018; 268:189-192. DOI: 10.1016/j.psychres.2018.05.033. View

15.

Steinberg D, Witztum J . Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30(12):2311-6. DOI: 10.1161/ATVBAHA.108.179697. View

16.

Jayanthi S, Ladenheim B, Cadet J . Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci. 1998; 844:92-102. View

17.

Maes M . Precision Nomothetic Medicine in Depression Research: A New Depression Model, and New Endophenotype Classes and Pathway Phenotypes, and A Digital Self. J Pers Med. 2022; 12(3). PMC: 8955533. DOI: 10.3390/jpm12030403. View

18.

Batki S, Harris D . Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia. Am J Addict. 2005; 13(5):461-70. DOI: 10.1080/10550490490512834. View

19.

Prakash M, Tangalakis K, Antonipillai J, Stojanovska L, Nurgali K, Apostolopoulos V . Methamphetamine: Effects on the brain, gut and immune system. Pharmacol Res. 2017; 120:60-67. DOI: 10.1016/j.phrs.2017.03.009. View

20.

Potula R, Hawkins B, Cenna J, Fan S, Dykstra H, Ramirez S . Methamphetamine causes mitrochondrial oxidative damage in human T lymphocytes leading to functional impairment. J Immunol. 2010; 185(5):2867-76. PMC: 3124898. DOI: 10.4049/jimmunol.0903691. View